Skip to content

Impacts of Clinical Pharmacist Services on Anticoagulation Management of Total Joint Arthroplasty

Impacts of Clinical Pharmacist Services on Anticoagulation Management of Total Joint Arthroplasty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043198
Enrollment
Unknown
Registered
2021-02-08
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Orthopedic Surgery

Interventions

baseline period:no clinical pharmacist services
intervention period: clinical pharmacist services

Sponsors

The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) The first total hip or total knee arthroplasty was performed in our hospital from January 1, 2016 to June 30, 2021; (2) the preoperative Doppler ultrasonography of both lower limbs confirmed negative; (3) the electronic medical records were complete.

Exclusion criteria

Exclusion criteria: (1) Revision arthroplasty, intra-articular debridement, postoperative infection filled with antibiotic bone cement were planned; (2) the preoperative Doppler ultrasonography of both lower limbs confirmed positive; (3) patients required long-term antithrombotic therapy due to several situations such as cerebral infarction, atrial fibrillation, coronary heart disease, valve replacement surgery.

Design outcomes

Primary

MeasureTime frame
the use of anticoagulant drugs;the rationality of medication;the incidence of thrombosis ;

Countries

China

Contacts

Public ContactJingjing Shang

The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University

shang0308@126.com+86 13921032480

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026